You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Patient, tumour and treatment characteristics (N = 42 patients)

From: Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity

Gender Male N = 16 (38.0%)
Female N = 26 (62.0%)
Tumour stage T4 N = 37 (88.1%)
T3 N = 1 (2.4%)
T2 N = 3 (7.1%)
T1 N = 1 (2.4%)
Site Head N = 36 (86.0%)
Body N = 5 (12.0%)
Tail N = 1 (2.0%)
PS (WHO) 0 N = 2 (5.0%)
1 N = 17 (41.0%)
2 N = 22 (52.0%)
3 N = 1 (2.0%)
Previous treatment None N = 8 (19.0%)
Chemotherapy only N = 23 (54.8%)
Chemoradiotherapy N = 4 (9.5%)
Palliative surgery (gastric/biliary bypass) + chemotherapy N = 2 (4.8%)
Curative surgery (Whipples/Resection) + chemotherapy N = 1 (2.4%)
Curative surgery (Whipples/Resection) + chemoradiotherapy N = 4 (9.5%)
SABR purpose PRIMARY (no other/prior treatment) N = 8 (19.0%)
ADJUVANT (within 6 months other primary treatment) N = 14 (33.3%)
CONSOLIDATION (>  6 months post-primary treatment to residual disease) N = 11 (26.2%)
RETREAT (>  6 months post-primary treatment to disease relapse) N = 9 (21.4%)